andidemia remains a significant cause for morbidity and mortality. Some recent epidemiological surveys have suggested overall declining mortality due to nosocomial Candida infections. This decrease is perhaps due to more effective recognition of risks factors for these infections and to more aggressive and effective early therapy, as declining mortality was associated with introduction of fluconazole which is widely used as pre-emptive therapy in ICU settings. However, attributable mortality due to Candida in selected ICU settings has remained constant despite advances in therapy of these infections. In addition, Candida is a major and increasing etiology associated with ICU sepsis. Coupled with these findings, is the awareness that yeasts other than Candida albicans, particularly C. glabrata, which is often less susceptible or resistant to antifungals, including fluconazole, have emerged has major pathogens in many centers. New antifungal, including the echinocandins as well as extended spectrum azoles, voriconazole and posaconazole, offer activity against many of these resistant yeasts so that the clinician is faced with options for approaching these pathogens. In this session, clinical options for the management of candidemia will be discussed using a case-based approach.
Full conference title:
42nd Annual Meeting Infectious Diseases Society of America
- Infectious Diseases Society of America 42nd